Stereocomplexes for the delivery of anti-cancer agents
US-2024350644-A1 · Oct 24, 2024 · US
Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
US11896584B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11896584-B2 |
| Application number | US-202218060823-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 1, 2022 |
| Priority date | Feb 17, 2016 |
| Publication date | Feb 13, 2024 |
| Grant date | Feb 13, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating or preventing a methicillin-sensitive and/or methicillin-resistant Staphylococcus aureus infection in a subject in need thereof, the method comprising administering to the subject an effective amount of (N—(((S)-3-(dibezo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 2. The method of claim 1 wherein the subject is a human. 3. The method of claim 1 wherein the subject is an animal. 4. The method of claim 1 further administering at least one or more antimicrobial compounds.
Assignees
Inventors
Classifications
- A61K31/4245Primary
Oxadiazoles · CPC title
- A61K45/06Primary
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
not condensed and containing further heterocyclic rings · CPC title
for tuberculosis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11896584B2 cover?
- The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
- Who is the assignee on this patent?
- Univ Johns Hopkins, Univ Of St Thomas, The Johns Hopkins Universty
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4245. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).